Authors
Enrico Borrelli, Francesco Boscia, Paolo Lanzetta, Marco Lupidi, Rodolfo Mastropasqua, Massimo Nicolò, Mariacristina Parravano, Federico Ricci, Giovanni Staurenghi, Maria Vadalà, Francesco Viola, Stela Vujosevic, Francesco Bandello
Published in
Eye (London, England). Sep 25, 2025. Epub Sep 25, 2025.
Abstract
Faricimab, a bispecific antibody targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), introduces a novel therapeutic option for diabetic macular oedema (DMO) and neovascular age-related macular degeneration (nAMD).
This consensus document, developed by an expert panel of Italian retina specialists, provides practical recommendations for the integration of faricimab into clinical practice.
The panel reviewed pivotal clinical trials, YOSEMITE and RHINE for DMO and TENAYA and LUCERNE for nAMD, which demonstrated faricimab's noninferiority to aflibercept in vision outcomes while offering extended dosing intervals up to 16 weeks. Key benefits include rapid and sustained fluid resolution, enhanced macular dryness, and reduced treatment burden for patients and healthcare systems. Recommendations cover treatment initiation, tailored management using treat-and-extend protocols, and strategies for switching from other anti-VEGF therapies.
The consensus highlights faricimab's potential to optimise outcomes for patients with DMO and nAMD while addressing real-world challenges, such as undertreatment and clinic resource constraints.
PMID:
40999227
Bibliographic data and abstract were imported from PubMed on 26 Sep 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 48
- Comments 0